Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29715

2.

Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.

Chen S, Chen X, Xiu YL, Sun KX, Zhao Y.

PLoS One. 2015 May 1;10(5):e0125714. doi: 10.1371/journal.pone.0125714. eCollection 2015.

PMID:
25933027
3.

Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2015 Apr 15;9:521. doi: 10.3332/ecancer.2015.521. eCollection 2015.

PMID:
25932045
4.

Metastatic ovarian carcinoma presenting as an incarcerated femoral hernia.

Beecher SM, O'Leary DP, McLaughlin R.

Int J Surg Case Rep. 2015 Apr 22;11:53-55. doi: 10.1016/j.ijscr.2015.04.024. [Epub ahead of print]

PMID:
25931301
5.

Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study.

Murphy JD, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang CM, Martinez ME, Sicklick JK.

Cancer. 2015 Apr 30. doi: 10.1002/cncr.29434. [Epub ahead of print]

PMID:
25930983
6.

Role of MyD88 expression in Epithelial Ovarian Cancer: A Literature Review [237].

Garg D, Mor GG, Silasi DA.

Obstet Gynecol. 2015 May;125 Suppl 1:76S-77S.

PMID:
25930575
7.

Cetuximab directly inhibits P-glycoprotein function in vitro independently of EGFR binding.

Chu C, Noël-Hudson MS, Bénard J, Ha-Duong T, Allaoui F, Farinotti R, Bonhomme-Faivre L.

Eur J Pharm Sci. 2015 Apr 27. pii: S0928-0987(15)00157-8. doi: 10.1016/j.ejps.2015.04.014. [Epub ahead of print]

PMID:
25930120
8.

ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high grade serous ovarian carcinoma.

Cheon DJ, Li AJ, Beach JA, Walts AE, Tran H, Lester J, Karlan BY, Orsulic S.

Carcinogenesis. 2015 Apr 29. pii: bgv059. [Epub ahead of print]

PMID:
25926422
9.

Different Patterns of Disease Spread between Advanced-Stage Type I and II Epithelial Ovarian Cancer.

Bergamini A, Candiani M, Taccagni G, Rabaiotti E, Viganò R, De Marzi P, Ferrari D, Mangili G.

Gynecol Obstet Invest. 2015 Apr 22. [Epub ahead of print]

PMID:
25925865
10.

Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study.

Rabinovich A, Ramanakumar AV, Lau S, Gotlieb WH.

Acta Obstet Gynecol Scand. 2015 Apr 3. doi: 10.1111/aogs.12642. [Epub ahead of print]

PMID:
25923364
11.

Paraneoplastic Cholestasis Associated With Ovarian Dysgerminoma.

Yeh KE, Marcus PS, Fong TL.

Obstet Gynecol. 2015 Apr 28. [Epub ahead of print]

PMID:
25923022
12.

Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer.

Aljada A, Saleh AM, Alkathiri M, Shamsa HB, Al-Bawab A, Nasr A.

Breast Cancer (Auckl). 2015 Apr 9;9:3-8. doi: 10.4137/BCBCR.S23156. eCollection 2015.

13.

SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells.

Wang HL, Lu RQ, Xie SH, Zheng H, Wen XM, Gao X, Guo L.

Asian Pac J Cancer Prev. 2015;16(8):3573-7.

14.

Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.

Zhang LY, Li PL, Xu A, Zhang XC.

Asian Pac J Cancer Prev. 2015;16(8):3517-22.

15.

Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.

Strehl JD, Wachter DL, Fiedler J, Heimerl E, Beckmann MW, Hartmann A, Agaimy A.

Ann Diagn Pathol. 2015 Apr 7. pii: S1092-9134(15)00056-8. doi: 10.1016/j.anndiagpath.2015.04.001. [Epub ahead of print]

PMID:
25920939
16.

Paraneoplastic autoimmune hemolytic anemia in ovarian cancer: a marker of disease activity.

Loh KP, Kansagra A, Asik A, Ali S, Dahiya S.

Rare Tumors. 2015 Feb 11;7(1):5598. doi: 10.4081/rt.2015.5598. eCollection 2015 Feb 11.

17.

[Clinicopathologic features observation of ovarian transitional cell tumors].

Wang L, Dong Y, Li Q, Li H, Sun X, Zhou X, Li X.

Zhonghua Bing Li Xue Za Zhi. 2015 Feb;44(2):118-22. Chinese.

PMID:
25916643
18.

Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.

Van de Putte G, Oben J, Prenen L, Schobbens JC, Vlasselaer J, Van Holsbeke C, Debrock G, Van Eycken P, de Jonge E.

Int J Gynecol Cancer. 2015 Apr 24. [Epub ahead of print]

PMID:
25914962
19.

Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J.

Arch Gynecol Obstet. 2015 Apr 26. [Epub ahead of print]

PMID:
25914073
20.

ARID1A Expression in Ovarian Clear Cell Carcinoma with an Adenofibromatous Component.

Nishikimi K, Kiyokawa T, Tate S, Iwamoto M, Shozu M.

Histopathology. 2015 Apr 23. doi: 10.1111/his.12721. [Epub ahead of print]

PMID:
25913291
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk